secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001559053-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance
---------------------------------------------------------------------

- Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.
- Revenue $51.1M (vs $2.8M), primarily from $50M Novo Nordisk milestone for coramitug Phase 3 enrollment.
- Updated FY2026 net cash used guidance to $18-23M (prior $50-55M); year-end cash ~$273M (midpoint), up $18M.
- Initiated up to $100M share repurchase program; repurchased 788,990 shares for $7.3M through Q1.
- PRX019 Phase 1 completed; potential $55M milestone if Bristol Myers Squibb advances by YE 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/0001559053-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/prta-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001559053-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer